GSK invests $100M to boost shingles vaccine adjuvant production in Hamilton, Montana

GlaxoSmithKline is spending $100 million to increase production at its vaccine facility in Hamilton, Montana, which makes adjuvants for vaccines including Shingrix. The expansion aims to address demand since Shingrix was approved in the US in 2017.

“GlaxoSmithKline is spending $100 million to increase production at its vaccine facility in Hamilton, Montana.”doi.org

• 1 source
• doi.orgGSK to boost shingles vaccine productionRyan CrossApr 29, 2019

Summarized from public sources; check the original articles before acting on it.